Retatrutide and Sleep Apnea in 2026: New Trial Results Show Up to Half of Patients Reaching Remission or Mild Disease

The results come from two parallel phase 3 studies, TRIUMPH-1-OSA and TRIUMPH-2-OSA, which together enrolled 691 adults with moderate-to-severe obstructive sleep apnea (OSA) plus overweight or obesity — one trial in people without type 2 diabetes, the other in people with it. Participants received weekly retatrutide at 4 mg, 9 mg, or 12 mg, or placebo, for 80 weeks. The primary measure was the change in the apnea-hypopnea index (AHI) — the number of times per hour that breathing stops or becomes dangerously shallow during sleep.

Participants started severely affected, with average baseline AHI values of roughly 56 to 59 events per hour. By week 80, according to the published trial data:

• In people without diabetes, the 9 mg dose cut AHI by an average of 34.3 events per hour and the 12 mg dose by 31.7 — versus a 9.9-event drop on placebo.
• In people with type 2 diabetes, AHI fell by 24.7 events per hour on 9 mg and 25.4 on 12 mg, versus 10.3 on placebo.
• More than half of patients on the two higher doses achieved at least a 50% reduction in AHI.
• Between 39% and 52% of retatrutide-treated patients met criteria for remission or mild disease without daytime sleepiness, compared with roughly 12% to 24% on placebo.

All of the differences against placebo were statistically significant, and the trials also showed a meaningful reduction in hypoxic burden — a measure of how much oxygen deprivation the body endures overnight, which is linked to cardiovascular risk.

Sleep apnea in people with obesity is driven in large part by fat deposits around the airway and chest that narrow the airway and make it collapse during sleep. Lose enough weight and the airway stays open — which is exactly the mechanism these trials confirmed.

Participants on the higher retatrutide doses lost an average of 17.9% to 22.2% of their body weight over the 80 weeks, versus roughly 5% on placebo. That is in line with what retatrutide — which activates three gut-hormone receptors (GLP-1, GIP, and glucagon) instead of the one or two targeted by current drugs — has shown elsewhere: earlier phase 2 data reached about 24% average weight loss, the strongest figure of any obesity medication tested to date.

The practical translation: the breathing improvement is not a separate pharmacological trick. It follows the weight loss. Which is encouraging, because it means patients who achieve comparable weight loss with today's approved medications can expect directionally similar benefits.

Retatrutide is not the first weight loss drug to post sleep apnea results. Tirzepatide (Zepbound) was approved by the FDA for moderate-to-severe OSA in adults with obesity in December 2024, after the SURMOUNT-OSA trials showed it cut AHI by roughly 30 events per hour — up to about a 63% reduction.

The new retatrutide numbers land in the same territory, with somewhat larger weight loss. That matters less as a head-to-head scorecard (the trials enrolled different populations and cannot be compared directly) and more as confirmation of a pattern: serious, sustained weight loss from incretin-based medication is now a legitimate treatment pathway for obesity-related sleep apnea, alongside CPAP rather than instead of it.

For patients today, the practical takeaway is that this pathway is already available. Tirzepatide — the active ingredient in JoeyMed's TIRZ HD program — is the proven, approved option, while retatrutide remains investigational.

Retatrutide's safety profile in these trials looked like other GLP-1-class drugs: the most common side effects were gastrointestinal — nausea, diarrhea, constipation, and dyspepsia — mostly mild to moderate and concentrated during dose escalation. Those effects are familiar to anyone on semaglutide or tirzepatide, and are usually manageable with slower titration and supportive care such as anti-nausea medication.

One caution that bears repeating: retatrutide is not approved or legally available anywhere, and headline results like these tend to drive people toward gray-market "research use only" peptides. The FDA has received reports of deaths linked to black-market retatrutide, and unregulated vials have no verified identity, sterility, or dose. No trial result justifies injecting an unapproved substance from an unverified source.

Eli Lilly's registrational TRIUMPH program spans more than 5,800 participants, and with the obesity and sleep apnea readouts now public, industry observers widely expect an FDA submission with potential approval in 2027. That is not a date to plan your treatment around — approval timelines slip, and insurance coverage takes longer still.

If sleep apnea or weight is affecting your health now, the evidence-backed moves are: keep using your CPAP if one has been prescribed (none of these trials suggest abandoning it), and talk with a licensed provider about whether an approved medication such as tirzepatide or semaglutide fits your health profile. GLP-1-class drugs are not right for everyone — they are generally avoided with a personal or family history of medullary thyroid carcinoma, MEN 2 syndrome, or a history of pancreatitis, and they require medical screening and follow-up.

JoeyMed's licensed providers prescribe physician-supervised weight loss treatment online, including high-dose tirzepatide — the same molecule already FDA-approved for obstructive sleep apnea — with ongoing clinical support and side-effect management. If you are carrying extra weight and waking up exhausted, an online visit takes a few minutes, and a provider will review your health history to determine whether treatment is appropriate for you. Learn more at JoeyMed Weight Loss or explore the TIRZ HD program to see whether you qualify.